Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
366
resultados
Última actualización
30/10/2026 [08:23:00]
Resultados 350 a 366 de 366
Resumen de: WO2026183555A1
Methods of treating a neurodegenerative disease in a subject in need thereof are provided. Exemplary methods include providing a biological sample from the subject; measuring an NfL530 peptide concentration in the biological sample; measuring at least one of an NfL284 peptide concentration and an NfL101 peptide concentration in the biological sample; determining at least one of an NfL530/NfL284 ratio and an NfL530/NfL101 ratio; and treating the subject based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio. In some embodiments, the biological sample is selected from whole blood, plasma, and cerebrospinal fluid. In some embodiments, the subject is determined to have ALS based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio.
Resumen de: WO2026183319A1
Described herein are methods of identifying cell-type specific proteins that are transmembrane on or internal to extracellular vesicles (EVs).
Resumen de: WO2025090763A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
Resumen de: CN122162053A
The present application relates to methods for quantifying citrullination and methods that can be used to assess the activity of agents including, for example, PAD4 (peptidyl arginine deiminase 4) modulators, such as small molecules or antibodies. In certain embodiments, the methods comprise assessing citrullination of one or more citrullination sites on a protein or peptide fragment thereof present in a biological sample.
Resumen de: AU2025215582A1
The present disclosure provides, e.g., signature peptide compounds corresponding to various full-length protein components of the complement enzymatic cascade (e.g., C1q, C1s, C3, C3p, C4, C4p, C5, C5p, FB, and FBp). In one aspect, the invention relates to using these signature peptides for measuring and/or monitoring activation of the complement pathway, e.g., in clinical samples, such as plasma, serum, CSF, aqueous humor, or vitreous humor.
Resumen de: AU2024293997A1
A machine learning model can be trained to predict brain tau or amyloid β status of a patient using, at least in part, biomarker data of the patient. The brain tau or amyloid β status can include one or more continuous-valued brain tau or amyloid β levels and/or concern brain tau or amyloid β levels in multiple regions of the brain of the patient. A prediction of brain tau or amyloid β status of the patient can be generated by applying the subject data of the patient to the machine learning model. The operations can further include providing the prediction of brain tau or amyloid β status of the patient. The machine learning model be used in selection of patients for treatment with an anti-tau therapy and/or an anti-amyloid therapy, in treatment of patients having or suspected of having Alzheimer's Disease (AD), or in monitoring of AD treatment efficacy.
Resumen de: SA520420801B1
Provided a re antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same. Fig 1.
Resumen de: MX2026001711A
The invention provides novel anti-IL-5 proteins, antibodies and IL-5 binding fragments thereof, which inhibit association of IL-5 with IL-5 receptor and are suitable for administration to a human or feline subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-5 protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-5-related disorders.
Resumen de: WO2025042785A1
Provided herein are compositions and methods for reducing levels of at least one biomarker in a subject. The at least one biomarker may include p75ECD, PGE-MUM, or both. In some cases, the compositions and methods provided herein involve administering to a subject an amount of a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor effective to reduce levels of the at least one biomarker in the subject.
Resumen de: CN122665107A
本发明属于生物医药领域，具体涉及胰岛素受体INSR‑α作为治疗靶点的应用。本发明提供了特异性结合胰岛素受体INSR‑α的抗体或胰岛素受体INSR‑α信号拮抗剂在制备用于预防和/或治疗肝纤维化的药物中的应用。同时，本发明还提供了一种筛选由MASLD/MASH引起的肝纤维化的药物的方法，所述方法包括，将待测物质给予施用对象；检测施用对象中肝星状细胞的活性；以及判断所述待测物质是否为候选药物的步骤。本发明通过实验证明，通过使用胰岛素受体INSR‑α的中和抗体结合INSR‑α或其信号拮抗剂抑制HSCs的活化，可减轻MASLD/MASH的肝纤维化进程。因此，本发明为由MASLD/MASH引起的肝纤维的治疗提供新途径。
Resumen de: CN122671666A
0001 本发明涉及一种快速检测微量血液样本中ApoE的微针贴片及其制备方法与应用，属于生物检测技术领域。本发明通过将微针贴片等离子处理后，包被ApoE捕获蛋白，获得快速检测微量血液样本中ApoE的微针贴片。本发明通过等离子体技术对微针表面进行处理，使其获得亲水性，从而可以包被特定蛋白，提高了对捕获蛋白的包被能力，增加了检测的灵敏度和准确性，且制备简单，成本可控。本发明获得的微针贴片用于检测ApoE，不仅具备传统血检的高灵敏度和高准确性，还比传统血检所需血液样本量大大减少，无需静脉抽血，可采用指血检测。相较于现有微针检测技术，本发明为血液样本定量结果，检测结果更可靠。
Resumen de: WO2025122947A1
Aspects of the disclosure include methods of monitoring and/or prognosing an adoptive cell therapy in a subject, comprising determining a level of endogenous SCF in a biological sample from the subject, in which the detection of a presence, absence, and/or amount of endogenous SCF is informative of the in vivo activation and/or expansion of the adoptive immune cells, the anti-tumor effect of the adoptive cell therapy, and/or the need for a treatment modification and/or extension. The disclosure also provides a method of treating a disease by administering at least one c-kit agonist (e.g., SCF) simultaneously or sequentially with an adoptive cell therapy.
Resumen de: CN122671656A
本发明公开了一种外泌体标志物及其在阿尔茨海默病诊断和治疗中的应用。本发明首次发现，AD患者外周血外泌体中ANXA7蛋白水平显著升高，且其诊断效能良好。本发明还首次揭示，在AD病理条件下，Aβ刺激的小胶质细胞通过外泌体将ANXA7递送至神经元，ANXA7进入神经元后诱导细胞凋亡和氧化应激，从而加速AD进展；使用外泌体抑制剂GW4869或敲低小胶质细胞ANXA7表达可显著减轻神经元损伤。基于上述发现，本发明提供了检测外泌体中ANXA7蛋白水平的试剂在制备AD诊断试剂盒中的应用，以及降低ANXA7表达或活性的物质、抑制外泌体分泌的物质在制备治疗AD的药物中的应用。本发明为AD的早期诊断和靶向治疗提供了新的分子标志物和干预策略。
Resumen de: CN122664983A
本发明涉及生物医药技术领域，具体公开了CLOCK蛋白在调控T‑2毒素致阿尔茨海默症关键因子表达中的应用，其技术要点为：本发明通过T‑2毒素诱导的SH‑SY5Y细胞模型发现：T‑2毒素可诱导721个差异表达基因，显著富集于p53信号通路及昼夜节律通路；T‑2毒素使CLOCK蛋白节律参数发生改变，中值由0.697升至0.861，峰相位由22.34h偏移至7.18h，并诱导p53延迟性持续激活（12h达峰值2.31倍）；CLOCK与p53存在双向调控，形成CLOCK‑p53信号轴；该信号轴通过驱动细胞衰老程序（SA‑β‑gal阳性面积24h达25.13%）介导AD关键因子稳态失衡，表现为APP下降（0.53倍）及p‑Tau（1.19倍）、T‑Tau（1.35倍）升高；CLOCK抑制剂CLK8可减轻Tau异常及衰老表型。本发明为AD防治提供了新靶点。
Resumen de: WO2025026904A1
The present invention relates to a microscopy method for obtaining a high-resolution image of a biological sample comprising a substance to be analyzed, wherein an image sequence is obtained by expansion microscopy comprising the steps: g. providing a biological sample, h. mixing said biological sample with a swellable material and forming bonds, preferably covalent bonds, between said substance to be analyzed and the swellable material, thereby forming a mixture, i. fragmenting said substance to be analyzed, j- expanding the mixture comprising said swellable material and said fragmented substance to be analyzed, k. staining the sample either before or after steps (a), (b), (c), or (d) and imaging the obtained mixture under an optical microscope equipped with a camera or a resonant scanner. It also refers to compounds and stabilization chambers for use in such a method.
Nº publicación: JP2026529406A 31/08/2026
Solicitante:
エルビス－リゲインエル・ピー
Resumen de: CN122341632A
The present invention provides material compositions and/or methods useful for the prevention and/or treatment of protein depletion (proteopenia), comprising material compositions that retain the natural function of peptides/proteins while limiting and/or preventing amyloid formation and/or aggregation of the peptides/proteins. Also provided are material compositions and formulations for enhancing peptide/protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, promoting peptide/protein synthesis and purification.
BOPI
Sede Electrónica
